Literature DB >> 9208095

Imidazoline receptors: qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity.

M Pigini1, P Bousquet, A Carotti, M Dontenwill, M Giannella, R Moriconi, A Piergentili, W Quaglia, S K Tayebati, L Brasili.   

Abstract

The observation that all the attempts to characterize imidazoline (I) receptors have been carried out with non-selective or poorly selective ligands prompted us to undertaken research aimed at developing selective ligand(s). In previous work using, as a starting point, cirazoline I, a potent alpha 1-adrenergic receptor agonist that also binds to I receptors, we showed that removal of the cyclopropyl ring (2) retains high affinity for I2 receptors while reducing alpha 1-adrenergic agonist activity. However, it was felt that this residual, albeit modest, alpha 1-adrenergic agonist activity might diminish the usefulness of compound 2, and we now report on our continuing efforts in this field. Starting from compound 2, we first eliminated the alpha 1-agonist component by isosteric replacement and then, by means of conformational restrictions on compound 7, succeeded in discovering tracizoline (9) and benazoline (12). These two new ligands with high affinity (pKi value 8.74 and 9.07, respectively) and unprecedented selectivity with respect to both alpha 2- (I2/alpha 2 7,762 and 18,621) and alpha 1- (I2/alpha 1 2,344 and 2,691) adrenergic receptors, are valuable tools in the study of I receptor structure and function. In addition, the large number of derivatives studied has allowed us to establish congruent qualitative structure-activity relationships and identify some structural elements governing affinity and selectivity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208095     DOI: 10.1016/s0968-0896(97)00009-6

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs.

Authors:  V Bruban; J Feldman; H Greney; M Dontenwill; S Schann; C Jarry; M Payard; J Boutin; E Scalbert; B Pfeiffer; P Renard; P Vanhoutte; P Bousquet
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Role of intracellular Ca2+ signaling in the antinociceptive and discriminative stimulus effects of the imidazoline I2 receptor agonist 2-BFI in rats.

Authors:  Justin N Siemian; Yanyan Qiu; Yanan Zhang; Jun-Xu Li
Journal:  Psychopharmacology (Berl)       Date:  2017-08-19       Impact factor: 4.530

3.  Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.

Authors:  Fabio Del Bello; Eleonora Diamanti; Mario Giannella; Valerio Mammoli; Laura Mattioli; Federica Titomanlio; Alessandro Piergentili; Wilma Quaglia; Marco Lanza; Chiara Sabatini; Gianfranco Caselli; Elena Poggesi; Maria Pigini
Journal:  ACS Med Chem Lett       Date:  2013-07-22       Impact factor: 4.345

4.  Discriminative stimulus effects of the imidazoline I2 receptor ligands BU224 and phenyzoline in rats.

Authors:  Yanyan Qiu; Yanan Zhang; Jun-Xu Li
Journal:  Eur J Pharmacol       Date:  2015-01-21       Impact factor: 4.432

5.  Characterization of the hypothermic effects of imidazoline I₂ receptor agonists in rats.

Authors:  David A Thorn; Xiao-Fei An; Yanan Zhang; Maria Pigini; Jun-Xu Li
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors.

Authors:  Dragan Urosevic; Urosevic Dragan; Stephan Schann; Schann Stephan; Jean-Daniel Ehrhardt; Ehrhardt Jean-Daniel; Pascal Bousquet; Bousquet Pascal; Hugues Greney; Greney Hugues
Journal:  Br J Pharmacol       Date:  2004-06       Impact factor: 8.739

7.  Discriminative stimulus effects of the novel imidazoline I₂ receptor ligand CR4056 in rats.

Authors:  Yanyan Qiu; Xiao-Hua He; Yanan Zhang; Jun-Xu Li
Journal:  Sci Rep       Date:  2014-10-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.